Dong-A St Co., Ltd., A Korean Pharmaceutical Company, And Beactica Therapeutics Ab, A Swedish Precision Oncology Company, Announced That They Have Mutually Agreed To Terminate Their Collaboration And Licensing Agreement. The Collaboration Focused On Developing Novel Candidate Compounds Against Multiple Cancer Targets Of Mutual Interest. The Partnership Has Been Productive, And Multiple Compound Classes Are Now In Various Stages Of Lead Generation And Optimization.As Part Of The Termination, Both Dong-A St And Beactica Therapeutics Will Gain Exclusive Global Rights For Further Development And Commercialization For Different Compounds Series Developed During The Collaboration. No Obligations To Pay Milestone Payments Or Royalties Will Remain For The Assets Divided Between Dong-A And Beactica. For A Limited Time, Each Company Is Entitled To A Revenue Share From Any Related Future Outlicensing Activities By The Other Party. Full Financial Details Remain Undisclosed.
